Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Human umbilical cord mesenchymal stem cell-derived small extracellular vesicles (hUCMSC-sEV) are nanoscale vesicles (exosomes) secreted by mesenchymal stem cells harvested from the umbilical cord. Developed by Shenzhen People's Hospital, these vesicles function as natural intercellular communication vehicles that transport a cargo of proteins, microRNAs (miRNAs), and other bioactive molecules to recipient cells. In the treatment of androgenetic alopecia, hUCMSC-sEVs are intended to promote tissue repair, mitigate inflammation, and stimulate hair follicle regeneration. The therapy is currently being evaluated in a Phase 1/2 clinical trial to assess its safety and efficacy compared to topical minoxidil in young men with hair loss.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on human umbilical cord mesenchymal stem cell-derived small extracellular vesicles.